Effect of lncRNA AK125437 on postmenopausal osteoporosis rats via MAPK pathway
Authors: X-M Wang
L-H Liu
Y-K Li
L-M Zhao
M Cui
H Wang
Journal: European review for medical and pharmacological sciences (2020)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: lncRNA AK125437; postmenopausal osteoporosis; MAPK pathway; RANKL; p-p38 MAPK
Affiliations: Department of Orthopedics, Jinan Traditional Chinese Medicine Hospital, Jinan, China. .

Abstract:  Objective: The aim of this study was to explore the effect of long non-coding ribonucleic acid (lncRNA) AK125437 on rats with postmenopausal osteoporosis via the mitogen-activated protein kinase (MAPK) pathway. Materials and methods: A total of 36 Sprague-Dawley rats were randomly divided into three groups, including normal group, model group, and an inhibitor group, with 12 rats in each group. Only ovaries were exposed in normal group. The postmenopausal osteoporosis model was established in model group. Meanwhile, the intervention was performed with inhibitor for 3 months after modeling in inhibitor group, followed by sampling. The expression of receptor activator of nuclear factor kappa-B ligand (RANKL) was detected via immunohistochemistry. The protein expression level of phosphorylated p38 (p-p38) MAPK was determined via Western blotting (WB). Furthermore, the expression level of lncRNA AK125437 and the content of serum estradiol were determined via quantitative Polymerase Chain Reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA), respectively. In addition, bone mineral density was measured using dual-energy X-ray bone mineral absorptiometer. Results: Immunohistochemistry results indicated that model group and inhibitor group had notably up-regulated positive expression level of RANKL than normal group (p&lt;0.05), which was remarkably lower in inhibitor group than model group (p&lt;0.05). Western blot results showed that compared with normal group, the protein expression level of p-p38 MAPK was substantially elevated in model and inhibitor groups (p&lt;0.05). Meanwhile, the protein expression level of p-p38 MAPK was markedly lower in inhibitor group than that in model group (p&lt;0.05). According to qPCR results, the expression level of lncRNA AK125437 was significantly up-regulated in both model group and inhibitor group compared with normal group, showing statistically significant differences (p&lt;0.05). However, no significant differences were observed between model group and inhibitor group (p&gt;0.05). ELISA results revealed that model group and inhibitor group had markedly lower estradiol content than normal group (p&lt;0.05). There was no statistically significant difference in the content of estradiol between the two groups (p&gt;0.05). According to the measurement results of bone mineral density, compared with normal group, bone mineral density was notably lower in model group and inhibitor group (p&lt;0.05). Furthermore, it was markedly higher in inhibitor group than that of model group (p&lt;0.05). Conclusions: LncRNA AK125437 affects the bone mineral density of rats with postmenopausal osteoporosis by activating the MAPK pathway. 

Retracted: No

PubPeer comments:
 Figure 4. Protein expression of p-p38 MAPK detected via WB. ![file] Loading control has appeared in a number of other papers by different authors. Upper right here, Figure 3 from [Cai t al (2020)] ,  Protein expression of RUNX2 detected via Western blotting . Upper left: Fig 3 from [Lu Lu (2020)] . Middle left: Fig 3 from [Chen et al (2019)] , and Lower left: Fig 3 from [Xie et al (2020)] . ![] , 
 Comparing the p-p38 MAPK band with Fig 3 from [Chang et al (2019)] , after a 180-deg rotation. ![file] ,